Italia markets closed

Incyte Corporation (0J9P.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
56,88+0,02 (+0,03%)
Alla chiusura: 06:19PM GMT
Schermo intero
Chiusura precedente56,86
Aperto57,35
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno56,65 - 57,35
Intervallo di 52 settimane50,81 - 75,42
Volume269
Media Volume2.831
Capitalizzazione123,998M
Beta (5 anni mensile)0,65
Rapporto PE (ttm)0,14
EPS (ttm)4,20
Prossima data utili30 apr 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

    MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto